Pacritinib
- TRADE NAME: Vonjo (CTI Biopharma)
- INDICATIONS: Primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L
- CLASS: Janus kinase (JAK) inhibitor, Janus kinase-2 inhibitor, Kinase inhibitor
- HALF-LIFE: 28 hours
FDA APPROVAL DATE: 02/28/2022
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Clarithromycin, CYP3A4 inducers , CYP3A4 inhibitors, Rifampin
No available data on use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
Page last updated 08/11/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
